Dexmedetomidine Pharmacokinetics During Continuous Venovenous Hemodialysis in Critically Ill Patients
试验速览
- 阶段
- 2 期
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Dexmedetomidine clearance by continuous venovenous hemodialysis
研究概览
简要总结
The purpose of this study is to determine dexmedetomidine pharmacokinetics during continuous renal replacement therapy on critically ill patients.
详细描述
Dexmedetomidine is a selective alpha-2-adrenergic agonist with sedative properties indicated for sedation of patients in the intensive care setting. ICU patients with acute kidney injury requiring renal replacement therapies frequently have changes in volume status causing alterations in drug pharmacokinetics. Although dexmedetomidine pharmacokinetics have been studied earlier on ICU patients, there is no information on its pharmacokinetics in critically ill patients needing continuous renal replacement therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical need for sedation
- •Acute kidney injury requiring renal replacement therapy (according to ICUs standard operating procedures)
排除标准
- •Severe bradycardia (HR < 50/min)
- •AV conduction block II-III (unless pacemaker installed)
- •Severe hepatic impairment (bilirubin > 101 umol/l)
- •Pregnancy or lactation
- •Age < 18
研究组 & 干预措施
dexmedetomidine
干预措施: Dexmedetomidine (Drug)
结局指标
主要结局
Dexmedetomidine clearance by continuous venovenous hemodialysis
时间窗: 10 hours from the start of the dexmedetomidine infusion
次要结局
未报告次要终点